Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade

This article was originally published on Nasdaq

Galmed Pharmaceuticals (GLMD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates — one of the most powerful forces impacting stock prices.

Responses